Jagsonpal Pharmaceuticals reports strong half-year profit and income growth

Jagsonpal Pharmaceuticals Limited reported a substantial increase in its unaudited financial results for the half-year ended September 30, 2025. Profit before tax for the half-year surged to INR 312.41m, up from INR 224.79m in the corresponding period of 2024. Total income for the half-year reached INR 1,559.29m, compared to INR 1,392.29m for the same period last year.

For the quarter ended September 30, 2025, the company's profit before tax stood at INR 168.10m, with total income at INR 774.92m. Net profit for the half-year was INR 233.69m. The company also reported total comprehensive income of INR 235.96m for the half-year.

Basic earnings per share for the half-year were INR 3.48, a notable increase from INR 2.52 in the prior year. The board of directors approved these results during its meeting on November 3, 2025.